The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.

After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.

The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.

NEW YORK – AstraZeneca on Monday said it has inked an exclusive license agreement with Shijiazhuang, China-based CSPC Pharmaceutical Group to develop an early-stage small molecule lipoprotein(a) ...

Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.

Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who used a chatbot or met with a genetic counselor.

Four US cancer centers are partnering with leading technology firms to analyze cancer patient data while maintaining privacy and regulatory compliance.

With help from the oversubscribed financing round, the Australian firm is eyeing early 2025 for a Phase I clinical trial of its TAG-72-targeting cell therapy.